Tovorafenib

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

From Diagnosis Delay to Targeted Therapy: A Retrospective Study of Pediatric DLGNT with a Comprehensive Literature Review.

From Diagnosis Delay to Targeted Therapy: A Retrospective Study of Pediatric DLGNT with a Comprehensive Literature Review.

Journal: Cancers

Published: December 31, 2025

Clinical experience with tovorafenib in adults with treatment-refractory high- and low-grade gliomas.

Clinical experience with tovorafenib in adults with treatment-refractory high- and low-grade gliomas.

Journal: Neuro-oncology practice

Published: December 29, 2025

Emerging Targeted Therapies and Ongoing Clinical Trials in Pediatric Brain Tumors

Emerging Targeted Therapies and Ongoing Clinical Trials in Pediatric Brain Tumors

Journal: No shinkei geka. Neurological surgery

Published: December 09, 2025

Rare gliomas: standard treatment approaches and new target therapies.

Rare gliomas: standard treatment approaches and new target therapies.

Journal: Current opinion in neurology

Published: September 24, 2025

Eco-conscious AQbD-guided stability-indicating RP-UPLC method for analysing Tovorafenib in bulk and dosage forms.

Eco-conscious AQbD-guided stability-indicating RP-UPLC method for analysing Tovorafenib in bulk and dosage forms.

Journal: Scientific reports

Published: September 22, 2025

Understanding Pharmacokinetic-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2024 to Better Manage the Risk of Drug Interactions With Concomitant Medications: A Review of Clinical Data From New Drug Applications.

Understanding Pharmacokinetic-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2024 to Better Manage the Risk of Drug Interactions With Concomitant Medications: A Review of Clinical Data From New Drug Applications.

Journal: Current therapeutic research, clinical and experimental

Published: August 07, 2025

The use of minor response, volumetric assessment, and growth rate kinetics as endpoints in grade 1-3 glioma clinical trials: a RANO perspective.

The use of minor response, volumetric assessment, and growth rate kinetics as endpoints in grade 1-3 glioma clinical trials: a RANO perspective.

Journal: Neuro-oncology

Published: July 22, 2025

New and Emerging Therapies for Patients with Low-Grade Glioma.

New and Emerging Therapies for Patients with Low-Grade Glioma.

Journal: CNS drugs

Published: June 06, 2025

Aggressive infantile melanoma arising in a congenital nevus with rare BRAF and BCOR mutations: a case report and literature review of pediatric melanoma.

Aggressive infantile melanoma arising in a congenital nevus with rare BRAF and BCOR mutations: a case report and literature review of pediatric melanoma.

Journal: Dermatology reports

Published: June 06, 2025

Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma.

Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma.

Journal: Journal of Cancer

Published: May 20, 2025

Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.

Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.

Journal: Nature medicine

Published: April 16, 2025

Response to a novel type II RAF inhibitor in diffuse leptomeningeal glioneuronal tumor with BRAF fusion.

Response to a novel type II RAF inhibitor in diffuse leptomeningeal glioneuronal tumor with BRAF fusion.

Journal: The oncologist

Published: April 03, 2025

Showing 1-12 of 32

Last Updated: 04/28/2026